DAYBUE (trofinetide) launched in US - Neuren earns US$40m
Filed with ASX · · 7 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- FDA approves Daybue - the first treatment for Rett syndrome
- Neuren reports 2022 full-year results
- Appendix 4E and 2022 full year accounts
- Q4 2022 quarterly activity and cash flow report
- Prader-Willi syndrome IND for NNZ-2591 approved by FDA
Later from Neuren Pharmaceuticals
- Q1 2023 quarterly activity and cash flow report
- Neuren receives US$40m milestone payment
- Neuren opens first site in US for Prader-Willi Phase 2 trial
- Neuren completes enrolment in Phelan-McDermid Phase 2 trial
- Neuren and Acadia expand global partnership for trofinetide
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals